

# 2nd Day of Immunotherapy, 30th May 2024

8:30	<b>Petr Cetkovský</b>   ÚHKT director - Welcome note <b>Jan Vydra</b>   ÚHKT, Praha Introduction to ÚHKT immunotherapy programme	
8:40	<b>Kim Vetterranta</b>   University of Helsinki Cellular therapy in acute lymphoblastic leukemia	
9:00	<b>Matti Korhonen</b>   FRCBS, Helsinki Genetically Modified Immune Cells for Cancer Therapy	
9:20	<b>Erja Kerkelä</b>   FRCBS, Helsinki Development and manufacturing of advanced cell therapies at the Finnish Red Cross Blood Service	
9:40	<b>Jan Vydra</b>   ÚHKT, Praha Clinical trials - CAR-T at UHKT - CD19, CD123	
10:00	<b>Vladimír Kolář</b>   BioTech a.s. Innovations in Immunotherapy: The Role of Simoa Assays in Enhancing CAR-T Therapy	
10:10	<b>Ondřej Pelák</b>   Becton Dickinson Czechia, s.r.o. BD Biosciences as Single Cell Analysis Partner at Every Level	<b>Break</b>
10:50	<b>Ondřej Vaněk</b>   PřF UK, Praha NK cell receptor-based immunotherapy of cancer: avidity instead of affinity?	10:20-10:50
11:10	<b>Petr Lesný</b>   ÚHKT, Praha ÚHKT Immunotherapy I – production, testing, quality control	
11:30	<b>Pavel Otáhal</b>   ÚHKT, Praha ÚHKT Immunotherapy II: Non-viral transfection technology for CAR-T production, our results and pipeline	
11:50	<b>Michal Šmída</b>   CEITEC, Brno Overcoming challenges of CAR-T cells targeting CD19 in chronic lymphocytic leukemia	
12:10	<b>Ondřej Hovorka</b>   SVEN BioLabs s.r.o. New imaging capabilities using EVIDENT SiVir detectors with infinite dynamic range	<b>Lunch</b>
13:50	<b>Robert Pytlík</b>   ÚHKT, Praha Commercial CAR-T immunotherapy	12:20-13:50
14:10	<b>Monika Holubová</b>   FN, Plzeň Invariant Natural-Killer T cells - future of allogeneic cellular immunotherapy?	
14:30	<b>Jan Musil</b>   ÚHKT, Praha Immunology of Acute Myeloid Leukemia	
14:50	<b>Tereza Dekojová</b>   FN, Plzeň Peripheral blood NK cells in multiple myeloma	
15:10	<b>Jan Frič</b>   ÚHKT, Praha Advanced testing strategies of NK cell function	
15:20-17:00	<b>Networking, coffee and cake</b>	